The hypothesize of this research is that rapamycin is effective and well-tolerated in teenagers with familial adenomatous polyposis (FAP). Rapamycin could be effective in blocking the formation of adenomas and/or their evolution by decreasing their size and number. Researchers aim to assess the safety profile of rapamycin in FAP adolescents using a 2 low dose regimen.
Children aged 12 to 17 at time of inclusion.
Patients with colonoscopy for diagnosis or follow-up of FAP.
≥ 5 polyps (> 2 mm) at initial colonoscopy (V1).
Free and informed consent, signed by both holders of parental authority/legal representative, with the accord of the minor patient.
Inability to understand the nature and goals of the study and/or communication difficulties observed by the investigator.
Contraindication to performing a colonoscopy.
< 5 polyps (>2 mm) registered during initial colonoscopy (V1).
Advanced disease with high-grade dysplasia adenoma or even adenocarcinoma in situ that should required colectomy